A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Neoplasms

Treatments: Drug: PF-06664178

Study type: Interventional

Funder types: Industry

Identifiers

NCT02122146

B7401001

2015-002704-84 (EudraCT Number)

Details and patient eligibility

About

To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Enrollment: 31 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available
• Performance Status of 0 or 1
• Adequate bone marrow, kidney and liver function
• Part 2 includes target expressing NSCLC, ovarian or breast cancer patients

Exclusion criteria

• Brain metastases requiring steroids
• Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)
• Active and clinically significant bacterial, fungal, or viral infection

Trial design

31 participants in 1 patient group

PF-06664178

Experimental group

Description:

Experimental

Treatment:

Drug: PF-06664178

Drug: PF-06664178